Resources Management Corp CT ADV Boosts Stake in Merck & Co., Inc. $MRK

Resources Management Corp CT ADV lifted its position in shares of Merck & Co., Inc. (NYSE:MRK) by 3,067.4% during the 4th quarter, HoldingsChannel reports. The fund owned 59,610 shares of the company’s stock after purchasing an additional 57,728 shares during the period. Resources Management Corp CT ADV’s holdings in Merck & Co., Inc. were worth $6,275,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Kingdom Financial Group LLC. purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth about $25,000. United Financial Planning Group LLC purchased a new stake in shares of Merck & Co., Inc. during the 3rd quarter worth about $31,000. High Note Wealth LLC boosted its stake in shares of Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after acquiring an additional 109 shares in the last quarter. IFC & Insurance Marketing Inc. purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth about $31,000. Finally, Gilpin Wealth Management LLC purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth about $32,000. 76.07% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Stock Up 0.0%

MRK opened at $119.05 on Monday. Merck & Co., Inc. has a twelve month low of $76.66 and a twelve month high of $125.14. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. The company has a 50-day moving average price of $116.55 and a 200 day moving average price of $113.32. The company has a market cap of $294.04 billion, a PE ratio of 33.54, a price-to-earnings-growth ratio of 2.68 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. During the same quarter in the prior year, the firm earned $2.22 EPS. The company’s revenue for the quarter was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Sell-side analysts expect that Merck & Co., Inc. will post 5.17 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio is 95.77%.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck Animal Health announced a definitive agreement to acquire TARGAN, a poultry biodevice company, which could strengthen Merck’s animal health division and broaden its technology-driven growth opportunities. Merck Animal Health to Acquire TARGAN
• Positive Sentiment: Merck saw unusually heavy call option buying, with traders purchasing 170,441 calls, a sharp jump versus normal volume that often signals bullish expectations from sophisticated investors.
• Positive Sentiment: Wells Fargo reiterated a buy rating on Merck, while another article highlighted that Wall Street’s overall bullish view continues to keep MRK on investors’ radar.
• Neutral Sentiment: Merck has also been featured in broader market commentary and “most searched” lists, suggesting rising attention rather than a new fundamental catalyst.
• Neutral Sentiment: One article noted Merck’s recent trading uptick but said it lagged the broader market, indicating modest price strength rather than a major breakout. Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Analyst Upgrades and Downgrades

MRK has been the topic of several recent analyst reports. Barclays initiated coverage on shares of Merck & Co., Inc. in a research note on Friday, February 20th. They set an “overweight” rating and a $140.00 target price on the stock. Wall Street Zen raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. Citigroup initiated coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a “neutral” rating and a $125.00 target price on the stock. Wells Fargo & Company lowered their target price on shares of Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Finally, UBS Group increased their target price on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $128.18.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.